Saturday, September 10, 2016 7:11:29 PM
"Hey, wait! Don't forget AstraZeneca's checkpoint inhibitor
At the very outset (2 weeks ago) I DID include Astra Zeneca: it is #7 in the NWBO STICKY: Collection of Expert Interviews:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124942557
as one of the authors of that study has impact at Astra Zeneca:
Disclosure of Potential Conflicts of Interest
R.E. Hollingsworth is a senior director, oncology and has ownership interest
(including patents) in MedImmune.-very expensive acquisition yrs ago of Astra's No potential conflicts of interest were disclosed by the other authors
As for the "overflow": it may have to wait as internal manpower at NWBO has been likely stretched to it's max.
GSK a favorite of Woodford and UK'ers ...... well I must confess I overlooked!
Still more than befuddles and IRKS me that Larry Smith latest report was a DOWNER. Those who feel differently have NOT been in the business and duking it out professionally for decades versus just a "passive" stockholder who has been buried for a reason vs blaming CEO Linda Powers. And he was on the All Star Team of Analysts of Institutional Investor All Star Team for Big Rx's and first to recommend AMGN, who interviewed me for Smith Barney's Research Dept, would spend the last 18 months plus with what I said would be an unproductive use of one's time dealing with regulators (the whole naked short side etc) as well as it is an ant vs an elephant war (fighting the AF/Manipulator $Multi BILLIONS and entrenched for last 20 yrs!)) along with NO response on presenting NWBO in it's prime Late Summer 2014 to Baker Bros. Well IMHO that's what the record and facts shows what happens with those who do not have an open mind IMHO! Similarly can be said on this site.
All are awaiting with abated breathe for REALITY.
Until then, only approximately a handful of us are brazen enough to stand up and call it as we see it as: Never easy to debunk the conventional wisdom or go against the crowd, along with taking a LARGE position.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
